BeiGene (BGNE) said Monday that BGB-16673, received a fast track designation from the US Food and Drug Administration for potentially treating relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The designation, with support from phase 1/2 safety and efficacy data, is to expedite FDA's review of BGB-16673 as a treatment for adults with CLL or SLL that has relapsed or did not respond to initial treatment, according to BeiGene.
Shares of the company were up 2.8% in recent Monday premarket activity.
Price: 199.23, Change: +5.41, Percent Change: +2.79
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。